Albany Molecular Research Inc. (AMRI)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.28+0.09 (+0.63%)
As of 3:59 PM EDT. Market open.
People also watch:
ARQLARRYALKSENZNANIK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open14.13
Prev Close14.19
Bid14.22 x 200
Ask14.23 x 1200
Day's Range14.13 - 14.50
52wk Range12.45 - 21.69
1y Target EstN/A
Market Cap594.26M
P/E Ratio (ttm)-14.63
Beta1.18
Volume292,482
Avg Vol (3m)258,895
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : August 25, 2016
    Capital Cube8 hours ago

    Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : August 25, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Albany Molecular Research, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day ... Read more (Read more...)

  • PR Newswireyesterday

    AMRI CEO to Present at Baird 2016 Global Healthcare Conference

    ALBANY, N.Y., Aug. 24, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Baird ...

  • PR Newswire2 days ago

    AMRI Licenses CRISPR-Cas9 Gene Editing Technology

    ALBANY, N.Y., Aug. 23, 2016 /PRNewswire/ -- AMRI (AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. "While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has significant utility that are critical to our customers' R&D projects, notably drug target assessment and in vitro model development for lead discovery and optimization," said Christopher Conway, Senior Vice President, Discovery and Development Services at AMRI.